#### 1 Article

# Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features

Authors: Hitoshi Dejima<sup>1,17</sup>, Xin Hu<sup>2,17</sup>, Runzhe Chen<sup>3,17</sup>, Jiexin Zhang<sup>4,17</sup>, Junya 4 Fujimoto<sup>1,17</sup>, Edwin R. Parra<sup>1</sup>, Cara Havmaker<sup>1</sup>, Shawna Hubert<sup>3</sup>, Dzifa Duose<sup>1</sup>, Luisa M. 5 Solis<sup>1</sup>, Dan Su<sup>5,6</sup>, Junya Fukuoka<sup>7</sup>, Kazuhiro Tabata<sup>7</sup>, Hoa Pharm<sup>7</sup>, Nicholas 6 Mcgranahan<sup>8</sup>, Baili Zhang<sup>1</sup>, Jie Ye<sup>3</sup>, Lisha Ying<sup>5,9</sup>, Latasha Little<sup>2</sup>, Curtis Gumbs<sup>2</sup>, Chi-7 Wan Chow<sup>1</sup>, Marcos Roberto Estecio<sup>10,11</sup>, Myrna C.B. Godoy<sup>12</sup>, Mara B. Antonoff<sup>13</sup>, Boris 8 Sepesi<sup>13</sup>, Harvey Pass<sup>14</sup>, Carmen Behrens<sup>3</sup>, Jianhua Zhang<sup>2</sup>, Ara A. Vaporciyan<sup>13</sup>, John 9 V. Heymach<sup>3</sup>, Paul Scheet<sup>15</sup>, J. Jack Lee<sup>16</sup>, P. Andrew Futreal<sup>2</sup>, Alexandre Reuben<sup>3\*</sup>, 10 Humam Kadara<sup>1\*</sup>, Ignacio Wistuba<sup>1\*</sup>, Jianjun Zhang<sup>2, 3,18\*</sup> 11

12

#### 13 Affiliations

Departments of <sup>1</sup>Translational Molecular Pathology, <sup>2</sup>Genomic Medicine, <sup>3</sup>Thoracic/Head
 and Neck Medical Oncology, <sup>4</sup>Bioinformatics & Computational Biology, <sup>10</sup>Epigenetics and
 Molecular Carcinogenesis, <sup>11</sup>Center of Cancer Epigenetics, <sup>12</sup>Thoracic Imaging,
 <sup>13</sup>Thoracic and Cardiovascular Surgery, <sup>15</sup>Epidemiology, <sup>16</sup>Biostatistics, The University of
 Texas MD Anderson Cancer Center, Houston, Texas, USA.
 <sup>5</sup>Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences,

20 Hangzhou, China.

21	<sup>6</sup> Department of Pathology, <sup>9</sup> Zhejiang Cancer Research Institute, Cancer Hospital of the
22	University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou,
23	China.
24	<sup>7</sup> Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences,
25	Nagasaki, Japan.
26	<sup>8</sup> Cancer Research United Kingdom-University College London Lung Cancer Centre of
27	Excellence, London, UK.
28	<sup>14</sup> Department of Cardiothoracic Surgery, New York University Langone Medical Center,
29	New York, NY 10016, USA.
30	<sup>17</sup> These authors contributed equally
31	<sup>18</sup> Lead Contact
32	*Correspondence: <u>AReuben@mdanderson.org</u> (A.R), <u>HKadara@mdanderson.org</u>
33	(H.K.), liwistuba@mdanderson.org (I.W.), Jzhang20@mdanderson.org (J.Z.)

34

# 35 SUMMARY

How anti-cancer immunity shapes early carcinogenesis of lung adenocarcinoma (ADC) is unknown. We characterized immune contexture of invasive lung ADC and its precursors by transcriptomic immune profiling, T cell receptor (TCR) sequencing and multiplex immunofluorescence. Our results demonstrated that anti-tumor immunity evolved as a continuum from lung preneoplasia, to preinvasive ADC, minimally-invasive ADC and frankly invasive lung ADC with a gradually less effective and more intensely regulated immune response including down-regulation of immune-activation pathways,

up-regulation of immunosuppressive pathways, higher infiltration of CD4+ T cells, lower
infiltration of CD8+ T cells, decreased T cell clonality, and lower frequencies of top T cell
clones in later stages. Driver mutations, HLA loss, chromosomal copy number aberrations
and DNA methylation changes may collectively impinge host immune responses and
facilitate immune evasion as a potential mechanism underlying outgrowth of the most fit
subclones in preneoplasia into dominant clones in invasive ADC.

49

#### 50 SIGNIFICANCE

There has been a drastic increase in the detection of lung nodules, many of which are 51 52 lung ADC precursors. The management of these lung nodules is controversial. We 53 discovered that immune activation and evasion have started at preneoplastic stage and lung ADC precursors may exhibit an overall better-preserved anti-tumor immune 54 therapeutic strategies 55 contexture suggesting reprograming the immune microenvironment patients with lung ADC precursors further 56 in prior to immunosuppression in invasive lung cancers may be beneficial. These findings have 57 served as the critical scientific rationale for our immunoprevention clinical trial IMPRINT-58 Lung (NCT03634241) recruiting individuals diagnosed with lung nodules at high risk 59 developing invasive lung cancers. 60

#### 61 **KEYWORDS**

Lung adenocarcinoma, premalignancy, atypical adenomatous hyperplasia, adenocarcinoma *in situ*, minimally invasive adenocarcinoma, tumor evolution, early carcinogenesis, immunoediting, immune microenvironment, immunogenomics

#### 65 **INTRODUCTION**

66 Despite significant advances in its management, lung cancer remains the leading cause 67 of cancer death worldwide (Siegel et al., 2020; Tan et al., 2016), largely due to late diagnosis at advanced stages when cures are generally unachievable (Barnett, 2017; 68 Borghaei et al., 2015; Siegel et al., 2020). Computed tomography (CT) scan-guided lung 69 70 cancer screening has demonstrated a reduction of lung cancer mortality by 26%-61% (de 71 Koning et al., 2020) highlighting the importance of early detection and intervention. These findings suggest that early cancer interception is crucial to reduce lung cancer incidence 72 73 and mortality. Yet, to date, randomized clinical trials on primary lung cancer prevention have only produced disappointing results (de Koning et al., 2020), primarily due to our 74 75 rudimentary knowledge of early phases in lung cancer development. Improved understanding of targetable molecular mechanisms underlying early lung carcinogenesis 76 may accelerate the development of precise diagnostic as well as effective preventive and 77 therapeutic strategies. 78

79 Lung adenocarcinoma (ADC) is the most common histological subtype of lung cancer. Recent studies has postulated that lung ADC may arise from atypical adenomatous 80 hyperplasia (AAH), the only recognized preneoplasia to lung ADC (Aoyagi et al., 2001; 81 Chiosea et al., 2007; Kitamura et al., 1999; Maeshima et al., 2010; Min et al., 2010; 82 Noguchi, 2010; Seki and Akasaka, 2007), which evolves into 83 preinvasive adenocarcinoma in situ (AIS) (Weichert and Warth, 2014), to micro-invasive lesion termed 84 minimally invasive adenocarcinoma (MIA) (Aoyagi et al., 2001; Travis et al., 2011) and 85 86 eventually frankly invasive ADC (Aoyagi et al., 2001; Travis et al., 2011). Early-stage lung ADCs and their precursors usually present as lung nodules with distinct radiologic 87

features called ground glass opacity (GGO). These lung nodules are often referred as indeterminate pulmonary nodules (IPN) without histologic diagnosis as the diagnostic yield from biopsy of GGO-predominate nodules is low and surgery is not the standard of care. This has subsequently led to the scarcity of appropriate materials to study the molecular profiles of lung ADC precursors (Izumchenko et al., 2015).

93 Carcinogenesis results from progressive accumulation of molecular abnormalities 94 (molecular evolution) (Vogelstein et al., 2013) and escape from host immune surveillance (immunoediting) (Schreiber et al., 2011). Our recent gene expression and genomic pilot 95 studies on lung ADC precursors have demonstrated distinct transcriptomic features 96 (Sivakumar et al., 2017) and progressive genomic evolution along the spectrum of AAH 97 to AIS, MIA and ADC (Hu et al., 2019). However, the extent to which immunoediting 98 sculpts early carcinogenesis of lung ADC and the underlying genomic and epigenetic 99 alterations associated with these immune features still remain to be determined. In the 100 current study, we performed immune gene expression profiling, T cell receptor (TCR) 101 sequencing and multiplex immunofluorescence (mIF) staining on a cohort of resected 102 AAH, AIS, MIA and invasive ADC lesions and paired morphologically normal lung tissues 103 104 (NL) to delineate the evolution of immune contexture, particularly T cell landscape across different stages of early lung ADC pathogenesis. We further leveraged whole exome 105 sequencing (WES) (Hu et al., 2019) and methylation data (Hu et al., 2020) from the same 106 107 cohort of IPNs to underscore the genomic and epigenetic alterations that may impinge on these immune features (Table S1 and Figure 1). 108

109

110 **RESULTS** 

# 111 Progressive decrease in overall immunity mirrors evolution from preneoplasia to

#### 112 invasive lung adenocarcinoma

113 To assess dynamic changes in the immune contexture during early lung carcinogenesis, 114 we performed immune profiling using the nCounter PanCancer Immune Profiling Panel (NanoString), which includes 770 genes from 14 different immune cell types, common 115 116 checkpoint inhibitors, cancer/testis antigens, and genes covering both the adaptive and innate immune response (Chen et al., 2016) on 47 resected pulmonary nodules (n=9 for 117 AAH, n=11 for AIS, n=21 for MIA, and n=6 for invasive ADC) and paired NL tissues (n=38). 118 119 There were no differences in age (p=0.55, Kruskal-Wallis test), sex (p=0.31, fisher's exact test) or smoking status (p=0.35, fisher's exact test) between patients with pulmonary 120 nodules of different histologic stages. In total, 291 genes were differentially-expressed 121 (DEGs). Interestingly, changes in the majority of DEGs, regardless of their direction, 122 exhibited a progressive pattern along the spectrum from NL, to AAH, AIS, MIA and ADC 123 (Table S2). Examples of progressively increased genes included immune suppressive 124 genes CD47 (protection of cancer cells from immune cell killing) (Soto-Pantoja et al., 125 2014), CD276 (inhibition of immune responses) (Picarda et al., 2016) and CTLA4 126 (checkpoint molecule) (Pardoll, 2012), while progressively decreased genes included 127 ENTPD1 (expressed on tumor-specific T cells) (Bastid et al., 2013), granzyme B (GZMB) 128 and perforin 1 (*PRF1*) (two cytotoxic molecules produced by T lymphocytes and natural 129 130 killer cells (NK cells) (Prakash et al., 2014; Tschopp et al., 1986) (Figure S1). Functional pathway analysis of DEGs revealed 26 significantly de-regulated pathways associated 131 with neoplastic evolution from NL to invasive ADC, of which, 23 were down-regulated 132 (Figure 2A). On the other hand, all three up-regulated pathways (systemic lupus 133

erythematosus (SLE) in B cell signaling, T cell exhaustion signaling and PARP signaling
pathways) could potentially impair immune response (Pan et al., 2020; Pantelidou et al.,
2019; Wherry and Kurachi, 2015). These results indicated an overall decreased immunity
in later-stage lesions.

We next de-convoluted gene expression profiling data using TIMER (Li et al., 2020) to 138 139 evaluate changes in immune cell composition. As shown in Figure 2B, CD4+ T lymphocyte infiltration progressively increased from NL to invasive ADC. Conversely, 140 infiltration of CD8+ T lymphocytes progressively decreased with neoplastic evolution 141 (Figure 2C) leading to significantly higher CD4/CD8 ratio in later-stage lesions (Figure 142 2D). Additionally, B cell infiltration progressively increased along the spectrum from NL 143 to invasive ADC (Figure 2E). Of particular interest, all 6 tertiary lymphoid structure (TLS) 144 markers CD19, MS4A1 (CD20), CXCL13, CXCR5, CCR7 and CCL19 (Cabrita et al., 2020) 145 (Figure S2) also progressively increased from NL to invasive ADC indicating a 146 progressive TLS aggregation, which may play a role in follicular regulatory T cell-147 mediated CD8+ T cell exclusion (Wang et al., 2020). Indeed, these TLS markers were 148 positively associated with CD4+ T cell infiltration, but negatively associated with CD8+ T 149 150 cell infiltration (Figure S3). To validate these findings, we applied TIMER to RNAseg data from an independent cohort previously published by our group and observed similar 151 results (Figure S4) (Sivakumar et al., 2017). 152

Taken together, these results suggest that immune evolution progressed as a continuum
 from preneoplasia to invasive lung ADC with a gradually less effective and more intensely
 regulated immune response.

156

# 157 Dynamic changes in T cell phenotype and infiltration define histologic stages of 158 early ADC development

159 We next performed multiplex immunofluorescence (mIF) using antibodies against 160 cytokeratin (CK), CD3, CD8, PD-1, PD-L1, CD68, CD45RO, GZMB and FoxP3 (Figure **3A, Figure S5** and **Figure S6**) on a subset of pulmonary nodules (n=9 for AAH, n=10 for 161 162 AIS, n=21 for MIA, and n=6 for invasive ADC) and paired NL (n =7) to assess the dynamic changes of various subtypes of T cells and their interaction with (pre-)malignant cells 163 during early lung carcinogenesis. Densities of infiltrating activated CTLs 164 (CD3+CD8+GZMB+) and regulatory T cells (Treg, CD3+CD8-FoxP3+) assessed by mIF 165 were positively correlated with corresponding CD8+ and CD4+ T cell infiltrate levels 166 derived from gene expression profiling, respectively (Figure S7A-B). Furthermore, 167 Treg/activated CTL ratio closely recapitulated CD4/CD8 ratio inferred from immune gene 168 expression profiling (Figure S7C). Correlations among immune subsets and between 169 immune components and epithelial cells across IPNs of different histologic stages 170 demonstrated that in normal tissues, densities of CK+ and CK+PD-L1+ cells were 171 positively correlated, as were Tregs and memory T cells, cytotoxic and activated cytotoxic 172 173 T cells (Figure S8A). For AAH, only total macrophages and activated cytotoxic T cells were positively correlated (Figure 3B). In AIS, PD-L1+ macrophages were positively 174 correlated with Tregs, antigen-experienced T cells and cytotoxic T cells (Figure 3C). For 175 176 MIA, CK cells were negatively correlated with total macrophages and memory T cells, while Tregs were positively correlated with antigen-experienced T cells and memory T 177 cells were correlated with cytotoxic and activated cytotoxic T cells (Figure 3D). Finally, in 178 ADC, PD-L1+CK+ cells were correlated with total and PD-L1+ macrophages, PD-L1+ 179

macrophages were correlated with total macrophages, and Tregs were correlated with
 memory T cells (Figure S8B). Overall, relationships between cell types varied widely
 across stages, highlighting the dynamic nature of tumor-immune interactions during tumor
 evolution.

184

# 185 **Progressively divergent TCR repertoire with neoplastic progression**

Because of the central role of T cells in tumor surveillance, we next sought to investigate 186 187 the T cell repertoire (Shah et al., 2011) by multiregional T cell receptor (TCR) sequencing 188 on 13 AAH, 11 AIS, 23 MIA and 10 ADC as well as 49 NL. We first assessed the T cell diversity using Inverse Simpson Index (Kaplinsky and Arnaout, 2016). T cell diversity was 189 190 positively correlated with infiltration of CD4+ T cells derived from gene expression profiling (Figure S9A) as well as densities of Tregs from mIF (Figure S9B) and increased steadily 191 192 from AAH to AIS, MIA and ADC (p<0.0001) (Figure 4A) in line with higher CD4+ T cells 193 in later stage lesions (Figure 2B). We then compared the distributions of T cell clonality across histologic stages, focusing on the most expanded T cell clones (Mansfield et al., 194 2018; Wang et al., 2019). As shown in Figure 4B and Figure S10, the top 10, 100, 200, 195 and 500 clones accounted for a higher frequency in the NLs, and gradually decreased in 196 AAH, AIS, MIA and invasive ADC (p<0.0001) implying suppressed T cell expansion 197 during early carcinogenesis of lung ADC. 198

199

# 200 Suppression of the T cell repertoire may occur at the preneoplastic stage

201 To further understand the T cell response at different histologic stages, we calculated T cell clonality, a metric indicating expansion and activation of T cell clones. T cell clonality 202 was positively correlated with infiltration of CD8+ T cells (r=0.561, p=4.863e-06), 203 204 activated CTLs (r=0.318, p=7.340e-03), GZMB expression (r=0.319, p=5.068e-02) and Th1 cytokines (r=0.473, p=3.923e-05) (Figure S11A-D), while negatively correlated with 205 infiltration of CD4+ T cells (r=-0.385, p=8.993e-04) and Tregs (r=-0.477, p=2.965e-05) 206 (Figure S11E-F) suggesting that T cell clonality was mainly driven by clonal expansion 207 of activated CTLs, with Treqs inhibiting CTL responses. Comparing T cell clonality among 208 different stages revealed the highest clonality in NL (Figure 4C) consistent with our 209 previous findings (Reuben et al., 2020). T cell clonality declined from NL to AAH 210 increasing in AIS/MIA and declining to its lowest level in ADC (Figure 4C). These results 211 212 suggest that early ADC pathogenesis is associated with local immunosuppression in TCR repertoire that may have commenced at the preneoplastic stage. 213

214

#### 215 Driver mutations affect the immune response in pre/early ADC

We next sought to explore the molecular features associated with the immune contexture 216 observed in these lesions. We first explored the two most frequently mutated driver genes 217 in this cohort EGFR and KRAS (Hu et al., 2019). Compared to EGFR-mutant lesions or 218 double wild-type lesions, KRAS-mutant lesions exhibited highest CD8+ T cell infiltration 219 and lowest CD4/CD8 T cell ratio inferred from immune gene expression; highest CTL 220 infiltration, highest effector memory cytotoxic T cell infiltration, highest CTL/Treg ratio from 221 222 mIF as well as highest T cell clonality measured by TCR sequencing (Figure S12). These trends remained similar when analyzing each histologic stage (Figure S13). These 223

findings are consistent with our previous studies in invasive lung cancers (Reuben et al., 2020) and emphasize the interplay between oncogene mutations and immune surveillance during early pathogenesis of lung adenocarcinoma.

227

# 228 Chromosomal copy number variations and HLA loss may contribute to impaired T

### cell responses

In light of recent studies suggesting immune evasion could be facilitated by an inability to 230 231 present neoantigens due to loss of HLA (McGranahan et al., 2017), we applied the 232 LOHHLA (loss of heterozygosity in HLA) algorithm (McGranahan et al., 2017) to WES 233 data from these lesions (Hu et al., 2019). LOH at the HLA loci was observed in 7%, 15% 234 and 33% of AIS, MIA and ADC respectively, but in none of AAH lesions (Figure S14A, p=0.005, Chi-Square test). Correlation with T cell infiltration derived from immune gene 235 expression profiling demonstrated that lesions with HLA LOH had similar CD4+ T cell 236 237 infiltration, but trends of lower CD8+ T cell infiltration and higher CD4/CD8 ratio although the difference did not reach statistical significance (Figure S14B-D). 238

239 Chromosomal copy number variation (CNV) has been reported to impact immune 240 microenvironment across different cancers (Davoli et al., 2017). We next investigated 241 whether CNV affected the immune landscape of these lung ADC precursors. Correlation 242 with T cell infiltration derived from gene expression profiling demonstrated burden of 243 allelic imbalance (AI), a subtle form of CNV, was negatively correlated with CD8+ T cell 244 infiltration, but positively correlated with CD4+ T cell infiltration and CD4/CD8 T cell ratio 245 (Figure S15A-C). Similar trend was also observed with CNV burden, although these

differences did not reach statistical significance (Figure S15D-F). Interestingly, HLA-LOH positive lesions exhibited significantly higher AI burden and CNV burden compared to that of HLA-LOH negative lesions (Figure S16). One plausible explanation is that the development AI, CNV or HLA LOH resulted from chromosomal instability (CIN) and cell clones with CIN may lead to higher CNV/AI burdens as well as increased likelihood of HLA loss, which could subsequently enable these cells escaping from anti-tumor immune surveillance and developing into dominant clones in the later-stage of neoplastic lesions.

253

# 254 Methylation status interacts with genomic alterations and impacts the immune 255 response during early lung cancer pathogenesis

256 Somatic mutations play central roles in activating anti-tumor immune responses through generating neoantigens that can be recognized by T cells (McGranahan et al., 2016; 257 Yarchoan et al., 2017). As shown in Figure S17, a progressive increase in total mutation 258 259 burden was observed from AAH to AIS, MIA and ADC. However, analysis of methylation data from reduced representation bisulfite sequencing (RRBS) of the same cohort of IPNs 260 (Hu et al., 2020) revealed that a significantly larger proportion of genes exhibited promoter 261 hypermethylation (>30% CpG methylated) in later-stage lesions, thus potentially 262 dampening the expression of neoantigens in later stage lesions. These data suggest that 263 promoter hypermethylation could contribute to neoantigen depletion and immune escape. 264 Furthermore, we assessed the impact of global methylation status, using long 265 interspersed transposable elements-1 (LINE-1) as a surrogate marker (Kankava et al., 266 267 2018; Ohka et al., 2011; Saito et al., 2010), on the immune microenvironment in these 268 lesions. Overall, global methylation level was negatively associated with CD4+ T cell

infiltration and CD4/CD8 ratio derived from gene expression profiling, Tregs infiltration
 and Treg/CD8 ratio from mIF (Figure S18) suggesting decreased global methylation was
 associated suppressive immune contexture.

272

#### 273 **DISCUSSION**

274 Cancer evolution is shaped by the interaction between cancer cells and host immune 275 surveillance, a process termed immunoediting consisting of elimination, equilibrium, and 276 escape phases (Dunn et al., 2002; Dunn et al., 2004a; Dunn et al., 2004b). It is well 277 documented that the majority of human cancers are infiltrated with various immune cells, 278 but often in an immunosuppressive microenvironment as remnant evidence of 279 immunoediting (Mittal et al., 2014; O'Donnell et al., 2019). T cell immunity is significantly compromised even in stage I lung cancers (Lavin et al.; Reuben et al., 2020) indicating 280 that these cancers have already begun evading immune surveillance. However, when 281 282 and how the elimination and equilibrium phases occur over the lung cancer evolution continuum is unknown. Therefore, investigating the molecular and immune landscape of 283 lung premalignancies is warranted to elucidate the timing of immune activation/evasion 284 and its underlying molecular mechanisms during early lung carcinogenesis. 285

In the current study, we leveraged a relatively large cohort of resected lung ADC precursors with available genomic and epigenetic profiling data to characterize the dynamic changes in the immune contexture across different consecutive developmental stages by gene expression profiling, mIF and TCR sequencing. To the best of our knowledge, this is the first systemic and comprehensive study on immune evolution

291 during early carcinogenesis of lung ADC and its potential underlying molecular basis. Overall, there was a more suppressive and tightly controlled immune response, 292 particularly T cell response, in later stage lesions highlighting that the dynamic 293 interaction between cancer cells and host immune surveillance was overall evolving 294 toward immune escape along with pathogenesis of lung ADC. Notably, dynamic 295 296 changes in immune contexture progressed as a continuum from preneoplasia AAH to pre-invasive AIS, to micro-invasive MIA and finally frankly invasive ADC without obvious 297 "step-wise" major leaps at transitions between different histologic stages. This is 298 299 consistent with the overall progressive genomic evolution from AAH to AIS, MIA and ADC (Hu et al., 2019) suggesting that early carcinogenesis of lung ADC is a gradual process 300 shaped by continuous interaction with host immune surveillance. Importantly, dynamic 301 302 immune activation and suppression have already started at preneoplastic stage. This is in line with a similar study on lung squamous cell carcinoma (SCC) precursors by 303 Mascaux and colleagues, which revealed evidence of both immune activation and 304 evasion along with evolution of preinvasive SCC lesions (Mascaux et al., 2019). Taken 305 together, these data advocate for therapy targeting the immune microenvironment in 306 patients with lung cancer precursors to prevent development of invasive lung cancers. 307

Identification of the molecular basis underlying immune activation and evasion may provide novel insights for understanding tumor-immune interactions and establishing biomarkers to select patients who may benefit from immunoprevention. WES and RRBS data available from the same cohort of pulmonary nodules provided the opportunity to depict the genomic and epigenetic features associated with the distinct immune landscape (Hu et al., 2020; Hu et al., 2019). Overall, oncogene mutations, HLA loss, CNV

burden, AI burden and methylation status were all found to associate with the immune contexture, similarly to advanced cancers (Fridman et al., 2017; Thorsson et al., 2018). For example, *KRAS* mutations correlated with more active immune response, while *EGFR* mutations, HLA loss, higher CNV burden and decreased global methylation status correlated with a cold immune microenvironment. However, associations with any single genomic or epigenetic feature were weak, suggesting heterogenous but convergent evolution towards immune escape during early lung carcinogenesis.

Our previous work suggested that early lung ADC carcinogenesis may predominantly 321 322 follow the clonal sweep model, whereby certain subclones in early-stage preneoplasia turn into dominant clones in later-stage diseases while unfit subclones are eliminated (Hu 323 et al., 2019), primarily by the host immune system. In the early phases of carcinogenesis, 324 stochastic genomic and epigenetic alterations lead to heterogeneous subclones with 325 various combinations of molecular features that define the distinct biology of each 326 subclone including survival ability under selective immune pressure. The impact of 327 genomic and epigenetic alterations on immune response is intertwined. For example, 328 methylation may directly affect immune response by regulating expression of immune 329 330 genes (Liu et al., 2017) or potential neoantigens (Serrano et al., 2011) or indirectly by increasing DNA vulnerability for development of CNV and somatic mutations that can 331 subsequently influence the immune microenvironment (Bakhoum and Cantley, 2018; 332 333 Porta-Pardo and Godzik, 2016). Global hypomethylation is known to associate with CIN (Eden et al., 2003) and increased rate of somatic mutations (Chen et al., 1998) and indeed, 334 global methylation level was negatively associated with TMB and CNV burden in this 335 336 cohort of lesions (Hu et al., 2020). Since high CNV burden is associated with a cold

337 immune microenvironment (Davoli et al., 2017) while high TMB can increase tumor immunogenicity and facilitate immune recognition and elimination of cancer cells (Jung 338 et al., 2019), the impact of global hypomethylation (associated with both high CNV burden 339 340 and TMB) on anti-cancer immunity is further complicated. In the end, the outgrowth of subclones is determined by the accumulated effects of all molecular aberrations. Only the 341 cells with the ideal combination of molecular features enabling their rapid proliferation and 342 escape from immune attack will survive and outgrow into the dominant clones in invasive 343 cancers. For example, though invasive lung ADCs tend to harbor a high mutation burden 344 345 that could lead to more active anti-tumor immune response, they also exhibited a higher CNV burden, higher likelihood of losing HLA and decreased global methylation, all of 346 which are associated with a cold tumor immune microenvironment (Jeschke et al., 2017; 347 Neal et al., 2018; Paulson et al., 2018; Rosenthal et al., 2019), resulting in an overall cold 348 immune microenvironment in invasive ADCs (lower CD8+ T cell infiltration, CTLs, and T 349 cell clonality, with higher CD4+ T cell infiltration and Tregs). 350

With the increasing implementation of CT-guided screening and advent of high-resolution 351 diagnostic CT scans, there has been a drastic increase in the detection of IPNs (Bellomi 352 353 et al., 2010; McWilliams et al., 2013), many of which are lung ADC precursors. However, their management remains controversial. Although surgical resection could potentially 354 offer cure in a large proportion of these patients, surgery-associated morbidity and high 355 356 cost have called surgical resection into question. Additionally, ~25% patients often present with multifocal diseases, which complicates surgery. We have previously 357 demonstrated (Hu et al., 2019; Sivakumar et al., 2017) that preinvasive lung ADC 358 precursors were molecularly simpler, and therefore theoretically easier to eradicate. In 359

the current study, we showed that lung ADC precursors may exhibit an overall betterpreserved anti-tumor immune landscape. In light of these findings, therapeutic strategies reprograming the tumor immune microenvironment in patients with lung ADC precursors prior to further immunosuppression in invasive lung cancers may be beneficial. The lung cancer immunoprevention clinical trial IMPRINT-Lung (NCT03634241) recruiting individuals with high-risk IPNs is currently underway to validate this hypothesis.

366

#### 367 ACKNOWLEDGEMENTS

368 This study was supported by the MD Anderson Khalifa Scholar Award, the National 369 Cancer Institute of the National Institute of Health Research Project Grant 370 (R01CA234629-01), the AACR-Johnson & Johnson Lung Cancer Innovation Science Grant (18-90-52-ZHAN), the MD Anderson Physician Scientist Program, the MD 371 Anderson Lung Cancer Moon Shot Program, Sabin Family Foundation Award, Duncan 372 Family Institute Cancer Prevention Research Seed Funding Program, the Cancer 373 Prevention and Research Institute of Texas Multi-Investigator Research Award grant 374 (RP160668) and the UT Lung Specialized Programs of Research Excellence Grant 375 (P50CA70907), Cancer Prevention and Research Institute of Texas (CPRIT) grant 376 RP150079. We thank Sally Boyd, Jinzhen Chen, and Rong Yao, Eric Sisson and Stan 377 Bujnowski for providing excellent technical support for high-performance cluster resource 378 http://hpcweb.mdanderson.edu/citing.html. We thank MD Anderson Cancer Center's 379 Epigenomics Profiling Core and its Science Park Next-Generation Sequencing Core 380 381 (supported by CPRIT Core Facility Support Award #RP120348) for performing RRBS profiling. 382

#### 383 AUTHOR CONTRIBUTIONS

- J.Z., I.W., H.K., and A.R. conceived, designed, and directed the study. H.D., X.H., R.C.,
- J.F., L.L., C.G., C.C., and J.Y. performed the experiments. X.H., Jiexin Z., N.M., S.H.,
- J.L., and Jianhua Z. conducted bioinformatic analyses. J.F., E.P., C.H., D.D., L.S., D.S.,
- J.F., H.P., B.Z., L.Y., performed pathologic assessment and tissue processing. M.E., M.G.,
- M.A., B.S., H.P., C.B., A.V., J.H., P.S., and P.A.F participated in data interpretation and
- clinical correlation. J.Z., R.C., H.D., H.K., A.R., and X.H. wrote the manuscript with
- 390 comments from all authors.

391

#### 392 **DECLARATION OF INTERESTS**

Dr. Zhang reports research funding from Merck, Johnson and Johnson, and consultant
fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed, Innovent
outside the submitted work. The other authors declare no competing financial interests.
Dr. Kadara reports funding form Johnson and Johnson and from Janssen
pharmaceuticals.

398

#### 399 FIGURE LEGEND

Figure 1. The immune evolution from preneoplasia to invasive lung
 adenocarcinoma and associated genomic and epigenomic features. Infiltration of B
 cells, CD4+ T cells, CD8+ T cells inferred from immune gene expression using TIMER;
 regulatory T cells (Treg) and activated cytotoxic T lymphocytes (CTL) measured by

404 multiplex immunofluorescence (mIF); T cell clonality and frequency of the top 100 T cell clones by TCR sequencing are shown in upper panel. Genomic alterations from whole 405 exome sequencing (WES) including EGFR/KRAS mutations, HLA loss, copy number 406 variation (CNV) burden, allelic imbalance (AI) burden, total number of mutations 407 associated with predicted neoantigens, total number of mutations associated with 408 409 predicted neoantigens without promoter methylation; global methylation status accessed by reduced representation bisulfite sequencing (RRBS) are shown in bottom panel. AAH: 410 typical adenomatous hyperplasia. AIS: adenocarcinoma in situ. MIA: minimally invasive 411 adenocarcinoma. ADC: invasive adenocarcinoma. 412

Figure 2. Progressively changes of immune cell infiltrations from preneoplasia to 413 invasive lung adenocarcinoma. (A) Significantly enriched functional pathways based 414 on the 291 differentially expressed genes by Ingenuity pathway analysis (IPA®; Ingenuity 415 Systems) software. Pathways with  $-\log (p-value) > 10 (p-values are obtained from provide the set of the set of$ 416 Fisher's right-tailed exact test) and an absolute z-score > 0.5 are shown. Pathways that 417 were predicted to be inhibited (negative Z scores) in later stages are in blue and pathways 418 that were predicted to be activated (positive Z scores) in later stages are in orange. The 419 420 heights of the bars indicate the significance of the enrichment (-log (p-value)) and the scales of the orange or blue colors represent the predicted directionality. Fractions of 421 immune cells including CD4+ T cells (**B**), CD8+ T cells (**C**), CD4/CD8 ratio (**D**) and B cells 422 423 (E) were estimated using TIMER based on the gene expression using nCounter PanCancer Immune Profiling Panel. Error bars indicate 95% confidence intervals and 424 solid point represent mean value in each stage. The difference of cell fraction among 425 different stages was evaluated using the Kruskal-Wallis H test. NL: Normal lung tissue, 426

AAH: Atypical adenomatous hyperplasia, AIS: Adenocarcinoma in situ, MIA: Minimally
invasive adenocarcinoma, ADC: Invasive adenocarcinoma.

Figure 3. Dynamic changes of various immune cells and their interaction with 429 430 epithelial cells across preneoplasia to invasive lung adenocarcinoma. (A) Representative multiplex immunofluorescence (mIF) images each histologic stage 431 432 analyzed by panel 1 and panel 2 markers. The correlation between immune cell subtypes 433 and CK+ epithelial cells measured by mIF in AAH (B), AIS (C) and MIA (D). Significant correlation was marked with \* (p<0.05). Red circles indicate positive correlations and blue 434 435 circles indicate negative correlations. The size of circles is proportional to the spearman's correlation co-efficient between each pair of cells. AAH: Atypical adenomatous 436 hyperplasia, AIS: Adenocarcinoma in situ, MIA: Minimally invasive adenocarcinoma. 437

Figure 4. Dynamic change in T cell repertoire from preneoplasia to invasive lung
adenocarcinoma. T cell diversity (A) and T cell clonality (C) in normal lung, AAH, AIS,
MIA and invasive ADC. (B) Distribution of T cell clones with frequency of top 1 (brown),
top 2 to 10 (black), top 11 to 100 (orange), top 101 to 200 (purple), top 201 to 500 (green),
top 501 to 1000 (red) and beyond 1000 (blue) in normal lung, AAH, AIS, MIA and invasive
ADC lesions.

444

#### 445 **STAR METHODS**

# 446 Patients and tissue processing

447 Specimens were collected from 53 patients presenting with pulmonary nodules, who 448 underwent surgical resection at Nagasaki Hospital (Japan) or Zhejiang Cancer Hospital (China) from 2014 to 2017 as described previously (Hu et al., 2019). The study was
approved by the Institutional Review Boards (IRB) at MD Anderson Cancer Center,
Nagasaki University Graduate School of Biomedical Sciences and Zhejiang Cancer
Hospital. Hematoxylin and eosin (HE) slides of each case were reviewed by experienced
lung cancer pathologists to confirm the diagnosis before further analyses.

#### 454 **DNA and RNA extraction**

After pathologic assessment, manual macro-dissection was performed to enrich 455 premalignant cells or cancer cells for DNA or RNA extraction. DNA or RNA was isolated 456 using the AllPrep® DNA/RNA FFPE Kit (Qiagen, Hilden, Germany) according to 457 manufacturer's instructions. Finally, the DNA samples were quantified by NanoDrop 1000 458 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and RNA was guantified 459 using the RNA High sensitivity kit on the Qubit 3.0 fluorometer (Thermo Fisher Scientific, 460 USA). RNA quality and integrity were evaluated with RNA integrity number (RIN) 461 (Schroeder et al., 2006), concentration (ng/µl), and size (nt) using RNA Screen Tape in 462 4200 Tape Station System (Agilent Technologies, USA). 463

#### 464 Gene profiling of immune cells using nCounter® platform

The nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA, USA), which contains 770 genes (including 730 immune associated genes and 40 housekeeping genes) using NanoString nCounter Analysis was applied for gene expression profiling as previously described (Cesano, 2015; Kulkarni, 2011). The data were imported into the nSolver 4.0 software (NanoString Technologies) for quality control (QC). After the QC was performed with default setting, background correction was done

471 with negative controls, and data was normalized by using the geometric mean of the 6 positive controls, and 40 housekeeping genes. We further performed quantile-472 normalization and log2 transformation to stabilize the variance. A one-way ANOVA test 473 474 was applied to identify differentially expressed genes (DEGs) in different stages. We modeled the p-values using a beta-uniform mixture (BUM) model, combined with false 475 discovery rate (FDR) to determine a cutoff for p-values (Pounds and Morris, 2003). The 476 DEGs, along with log ratios were then evaluated with Ingenuity Pathway Analysis (IPA) 477 software (Quiagen, Hilden, Germany) (Kramer et al., 2014) to identify pathways that are 478 enriched by these DEGs. We performed a Core Analysis with species set to human and 479 tissue set to lung. IPA identifies the top canonical pathways associated with the list of 480 DEGs by the Fisher's exact test to ascertain enrichment. IPA also calculates a z-score to 481 predict activation status of the pathway by comparing input genes and the stored activity 482 pattern. 483

# 484 Multiplex immunofluorescence staining

All samples were confirmed to be appropriate for multiplex immunofluorescence (mIF) 485 analysis based on tissue quality and availability using the HE staining of same lesion by 486 the experienced pathologist. The manual mIF staining was performed on unstained slides 487 of FFPE samples using the Opal 7-Color fIHC Kit (Akoya Biosciences, USA) as previously 488 described (Parra et al., 2018). Eight immune markers were placed in two 6-antibody 489 490 panels before the stained slides were scanned by Vectra multispectral microscope (Akoya Biosciences, USA). Panel 1 contained pancytokeratin (AE1/AE3; epithelial marker; 491 492 dilution 1:300; Dako, Carpinteria, CA), PD-L1 (clone E1L3N, dilution 1:100; Cell Signaling 493 Technology, Beverly, MA), PD1 (clone EPR4877-2, dilution 1:250; Abcam, Cambridge,

494 MA), CD3 (T lymphocyte marker; dilution 1:100; Dako), CD8 (cytotoxic T cell marker; clone C8/144B, dilution 1:20; Thermo Fisher Scientific, Waltham, MA), and CD68 495 (macrophage marker; clone PG-M1, dilution 1:450; Dako). Panel 2 contained 496 pancytokeratin, CD3, CD8, CD45RO (memory T cell marker; clone UCHL1, ready to use; 497 Leica Biosystems, Buffalo Grove, IL), Granzyme B (cytotoxic lymphocyte marker; clone 498 F1, ready to use; Leica Biosystems), and FoxP3 (regulatory T cell marker; clone 206D, 499 dilution 1:50; BioLegend, SanDiego, CA). Human tonsil FFPE tissues were used with 500 each individual antibody on same fluorochrome assay to build the spectral library, and 501 were also used with and without primary antibodies as positive and negative 502 (autofluorescence) controls, respectively. The stained slides were scanned with Vectra 503 3.0 multispectral microscope system (Akoya Biosciences, USA) under fluorescent 504 505 illumination. These mIF assays followed our previous publication (Francisco-Cruz et al., 2020). 506

#### 507 Multispectral analysis

508 The five individual fields for multispectral analysis were selected from areas of interest in a scanned low magnification (x10) image on Phenochart1.0.9 (Akoya Biosciences, USA). 509 510 The five high magnification (x20) fields for mIF analysis were carefully selected by experienced pathologists after comparing with HE slides to capture malignant and 511 premalignant cell cluster and various elements of heterogeneity. The corresponding 512 normal fields were selected in the farthest field of tumor periphery with morphological 513 normal tissue on the same slide (Figure S5A). The selected high magnification field was 514 total 1.6725 mm<sup>2</sup> in size (669×500µm per field) (Figure S5B). Each field with panel 1 and 515 panel 2 were overlapped with sequential sections. The target areas were analyzed by in 516

Form 2.4.4 software (Akoya Biosciences, USA). The area was divided into two 517 compartments: the epithelial compartment (the alveolar wall and septal or malignant cell 518 nests) and alveolar air space or tumor stroma compartment (Figure S5C). The individual 519 520 cells were recognized by DAPI nuclei staining (Figure S5D). Panel 1 contained the colocalization patterns as follows: PD-L1 expressing CK+ cells (CK+PD-L1+), total T 521 lymphocytes (total CD3+), cytotoxic T lymphocytes (CD3+CD8+), antigen experienced T 522 lymphocytes (CD3+PD-1), antigen experienced cytotoxic T lymphocytes (CD3+CD8+PD-523 1+), total macrophages (total CD68+), and PD-L1 expressing macrophages (CD68+ PD-524 L1+). Panel 2 contained the co-localization patterns as follows: total T lymphocytes (total 525 CD3+), cytotoxic T lymphocytes (CD3+CD8+), activated cytotoxic T lymphocytes 526 (CD3+CD8+GB+), memory T lymphocytes (CD3+CD45RO+), effector/memory T 527 528 lymphocytes (CD3+CD8+CD45RO+), regulatory T lymphocytes (CD3+FOXP3+CD8-), and memory/regulatory T lymphocytes (CD3+CD45RO+FOXP3+) (Figure S5). The 529 percentage of the total nucleated cell density from each individual cell phenotyping 530 population was used for further analysis. 531

# 532 TCRβ amplification and sequencing

Immunosequencing of the CDR3 regions of human TCRβ chains was performed using
the protocol of ImmunoSeq (Adaptive Biotechnologies, hsTCRβ Kit) and T cell clonality
and diversity were calculated as described previously (Reuben et al., 2017; Reuben et al., 2020).

Briefly, T cell clonality is a metric of T cell proliferation and reactivity, and it is defined as
1-Pielou's evenness and is calculated on productive rearrangements by:

$$1 + \frac{\sum_{i}^{N} p_i \log_2(p_i)}{\log_2(N)}$$

539

540 Where p<sub>i</sub> is the proportional abundance of rearrangement i, and N is the total number of 541 rearrangements. Clonality ranges from 0 to 1: values approaching 0 indicate a very even 542 distribution frequency of different clones (polyclonal), whereas values approaching 1 543 indicate a distinct asymmetric distribution in which a few activated clones are present at 544 high frequencies (monoclonal).

545 We also applied Inverse Simpson in order to observe T cell diversity, the sum over all 546 observed rearrangements of the square fractional abundances of each rearrangements 547 using productive templates.

$$\frac{1}{\sum_{i=1}^{S} p_i^2}$$

550 Where p<sub>i</sub> is the proportional abundance of rearrangement i, and S is the total number of 551 rearrangements. Inverse Simpson ranges from 1 to infinite, where a sample with little 552 variation or abundance has a value approaching 1, and a maximally diverse and evenly 553 distributed sample has a value approaching infinite.

# 554 Analysis of genomic and methylation profiling data

555 Genomic and methylation data were generated and processed in previous studies as 556 described (Hu et al., 2020; Hu et al., 2019). Somatic mutations, allelic imbalance (AI), 557 copy number variations (CNV), oncogene mutations, global methylation data were

558 directed from above mentioned studies. The following additional analyses were 559 performed on the genomic data.

#### 560 Detection of allele-specific HLA loss

Class I HLA alleles for each HLA gene was inferred by POLYSOLVER using a two-step 561 Bayesian classification approach (Shukla et al., 2015). This approach takes into account 562 the base qualities of aligned reads, observed insert sizes, as well as the ethnicity-563 dependent prior probabilities of each allele (Shukla et al., 2015). Tumor purity and ploidy 564 were estimated using ASCAT (Van Loo et al., 2010). We then applied LOHHLA (Loss Of 565 Heterozygosity in Human Leukocyte Antigen) algorithm (McGranahan et al., 2017) to 566 detect allele-specific HLA loss in each sample. In brief, logR and BAF across each HLA 567 568 gene loci was obtained by binning the coverage at mismatch positions between homologous HLA alleles, and HLA haplotype specific copy numbers were then calculated 569 based on logR and BAF value from the corresponding bin adjusted by tumor purity and 570 ploidy. The median value of binned allelic copy number was used to determined LOH. 571 where a copy number of < 0.5 indicated allele loss and AI was determined if p< 0.01. 572

#### 573 Statistical Analysis

574 Different statistical models were applied to assess the association among immune data, 575 genomic data and methylation data. When assessing association between two variables, 576 different tests were applied depending on the types of variables. For association between 577 two continuous variables, spearman's rank correlation test was used. For association 578 between one continuous variable and one categorical variable, Wilcoxon rank-sum test 579 (categorical variable with two levels) and Kruskal-Wallis test (categorical variable with

580 more than two levels) were applied. The FDR method was used for multiple testing 581 adjustment of p-values (Benjamini and Hochberg, 1995). All p-values are calculated with 582 two-sided test, and p<0.05 was considered to be statistically significant.

# 583 DATA AVAILABILITY

The data from WES has been deposited at European Genome-phenome Archive (EGA), 584 585 which is hosted by The European Bioinformatics Institute (EBI) and the Centre for Genomic Regulation (CRG) under the accession code: EGAS00001004960 586 [https://www.ebi.ac.uk/ega/datasets/EGAD00001004960]. All other data may be found 587 within the main manuscript or supplementary Information or available from the authors 588 upon request. 589

590

## 592 SUPPLEMENTAL INFORMATION

# 593 SUPPLEMENTAL FIGURE LEGENDS

Figure S1. Example genes differentially expressed from preneoplasia to invasive lung adenocarcinoma. Gene expression of *CD47* (**A**), *CD276* (**B**), *CTLA4* (**C**), *ENTPD1* (**D**), *GZMB* (**E**), *PRF1* (**F**) was performed using the nCounter PanCancer Immune Profiling Panel (Nanostring). The difference in expression of each gene among different stages was evaluated using the Kruskal-Wallis H test. AAH: typical adenomatous hyperplasia. AIS: adenocarcinoma in situ. MIA: minimally invasive adenocarcinoma. ADC: invasive adenocarcinoma.

Figure S2. Expression of tertiary lymphoid structure (TLS) marker genes from 601 602 preneoplasia to invasive lung adenocarcinoma. Gene expression of B cell marker CD19 (A) and MS4A1 (CD20) (B); follicle formation markers CXCL13 (C) and CXCR5 603 (D); T lymphocyte homing markers CCL19 (E) and CCR7 (F) was performed using the 604 605 nCounter PanCancer Immune Profiling Panel (Nanostring). The difference in expression of each gene among different stages was evaluated using the Kruskal-Wallis H test. AAH: 606 typical adenomatous hyperplasia. AIS: adenocarcinoma in situ. MIA: minimally invasive 607 adenocarcinoma. ADC: invasive adenocarcinoma. 608

Figure S3. Expression of TLS marker genes was associated with B cells, CD4+
Iymphocytes and CD8+ lymphocytes. Gene expression profiling was performed using
the nCounter PanCancer Immune Profiling Panel (Nanostring). Infiltration of B cells,
CD4+ T cells and CD8+ T cells was estimated using TIMER based on the gene
expression using nCounter PanCancer Immune Profiling Panel. The association between

the expression of each TLS marker gene and B cells, CD4+ T cells and CD8+ T cells
were evaluated using xxx test.

Figure S4. Progressively changes of immune cell in filtration normal lung, 616 617 preneoplasia and invasive lung adenocarcinoma. Immune cell fractions including CD4+ T cells (A), CD8+ T cells (B), CD4 /CD8 ratio (C), B cells (D) were estimated using 618 619 TIMER based on previously published RNA sequencing data from an independent cohort 620 (GSE102511). Error bars indicate 95% confidence intervals and solid point represent 621 mean value in each stage. The difference of cell fraction among stages was evaluated 622 using the Kruskal-Wallis H test. NL: Normal lung tissue, AAH: Atypical adenomatous hyperplasia, ADC: Invasive adenocarcinoma. 623

Figure S5. Quantitative image analysis of multiplex immunofluorescence image data. (A) After immunofluorescent staining, high magnification fields of interest were selected in both malignant (premalignant) and non-malignant regions. The non-malignant fields at the farthest regions from malignant (premalignant) regions with morphologically normal histology were selected. (B) Representative images from Panel 1 and Panel 2. (C) The selected fields were divided into two areas: epithelium and alveolar space. (D) Individual cells were recognized by DAPI (nuclear staining).

Figure S6. Subtyping immune epithelial cells multiplex 631 and by **immunofluorescence.** Cell subtypes were defined as PD-L1 expressing epithelial cells 632 (AE1/AE3+PD-L1+), T lymphocytes (CD3+), antigen-experienced T cells (CD3+PD-1+), 633 cytotoxic T lymphocytes (CTL, CD3+CD8+), antigen-experienced CTL (CD3+CD8+PD-634 1+), macrophages (CD68+) and PD-L1 expressing macrophages (CD68+PD-L1+) in 635 panel 1 (left); and activated CTL (CD3+CD8+granzyme B+), memory T cell 636

(CD3+CD45RO+), memory CTL (CD3+CD8+CD45RO+), regulatory T cell (CD3+CD8FoxP3+), memory/regulatory T cell (CD3+CD45RO+FoxP3+) in panel 2 (right).

Figure S7. The correlation between immune cell subtypes measured by multiplex 639 immunofluorescence and T cell subtypes inferred from immune gene expression. 640 Fractions of immune cells including CD8+ T cells (A), CD4+ T cells (B) and CD4/CD8 641 642 ratio (C) estimated using TIMER based on the gene expression from nCounter PanCancer Immune Profiling Panel (y-axis) were correlated to activated CTL 643 (CD3+CD8+granzyme B+), regulatory T cell (CD3+CD8-FoxP3+) and Treg/activated CTL 644 ratio respectively (x-axis). All fraction and ratio were log2 transformed for visualization. 645 The correction coefficient (rho) was assessed by Spearman's rank correlation test. 646

Figure S8. Various subtypes immune cells and their interaction with epithelial cells in normal lung tissues and invasive lung adenocarcinoma. The correlation between immune cell subtypes and CK+ epithelial cells measured by mIF in normal lung (**A**) and invasive lung adenocarcinoma (**B**). Significant correlation was marked with \* (p<0.05). Red circles indicate positive correlations and blue circles indicate negative correlations. The size of circles is proportional to the spearman's correlation co-efficient between each pair of cells. ADC: Invasive adenocarcinoma.

Figure S9. Correlation between T cell diversity and regulatory T cells. T cell diversity
was positively correlated with infiltration of CD4+ T cells derived from immune gene
expression using TIMER (A), regulatory T cells from multiplex immunofluorescence (mIF)
(B). The correction coefficient (rho) was assessed by Spearman's rank correlation test.

#### **Figure S10. Progressive decrease of top T cell clone frequencies from preneoplasia**

to invasive lung adenocarcinoma. Frequencies of (A) top 10, (B) tope 100, (C) top 200
and (D) top 500 T cell clones in the Normal (yellow), AAH (blue), AIS (red), MIA (green)
and ADC (purple). The difference between different stages were assessed by the KruskalWallis H test.

Figure S11. Correlation between T cell clonality and different T cell subtypes. T cell
clonality was positively correlated with infiltration of CD8+ T cells inferred from gene
expression by TIMER (A), activated cytotoxic T cells (B) by mIF, expression of GZBM (C)
and Th1 cytokines (INFG, IL12A and IL12B) (D) but negative correlated with infiltration of
CD4+ T cells derived from gene expression by TIMER (E) and regulatory T cells by mIF
(F). The correction coefficient (rho) was assessed by Spearman's rank correlation test.

Figure S12. The impact of oncogene mutations on T cell features. Comparison of infiltration of CD8+ T cells inferred from gene expression by TIMER (A), cytotoxic T cells (CTL) (B) by mIF, CD4/CD8 ratio inferred from gene expression by TIMER (C), Effector memory cytotoxic T cells by mIF (D), CTL/Treg ratio (E) by mIF, T cell clonality by TCR sequencing (F) in lesions with *EGFR* mutation (pink), *KRAS* mutation (orange) and wildtype for both *KRAS* and *EGFR* (green). The difference was assessed by Wilcox-rank sum test.

Figure S13. The impact of oncogene mutations on T cell features by different histologic stages. Comparison of infiltration of CD8+ T cells inferred from gene expression by TIMER (**A**), cytotoxic T cells (CTL) **B**) by mIF, CD4/CD8 ratio inferred from gene expression by TIMER (**C**), Effector memory cytotoxic T cells by mIF (**D**), CTL/Treg ratio (**E**) by mIF, T cell clonality by TCR sequencing (**F**) in lesions with *EGFR* mutation

(pink), *KRAS* mutation (orange) and wildtype for both *KRAS* and *EGFR* (green) in AAH,
AIS, MIA and ADC. The difference was assessed by Wilcox-rank sum test. AAH: Atypical
adenomatous hyperplasia, AIS: Adenocarcinoma in situ, MIA: Minimally invasive
adenocarcinoma, ADC: Invasive adenocarcinoma.

Figure S14. Loss of heterozygosity of HLA (HLA LOH) in different histologic stages from preneoplasia to invasive lung adenocarcinoma and its potential impact on immune contexture. (A) The proportion of AAH, AIS, MIA and ADC lesions had evidence of HLA-LOH. Chi-squared test were used to assess the difference among different histologic stages. The difference of infiltration of CD4+ T cells (B), CD8+ T cells (C) and CD4/CD8 ratio (D) inferred from gene expression by TIMER between lesions with (purple) and without (green) HLA-LOH.

Figure S15. The potential impact of chromosomal copy number changes on immune infiltration. The correlation between allelic imbalance (AI) burden (number of AI events) and infiltration of CD4+ T cells (**A**), CD8+ T cells (**B**), CD4/CD8 ratio (**C**) inferred from gene expression by TIMER. The correlation between copy number variation (CNV) burden (normalized as the number of genes with CNV) and infiltration of CD4+ T cells (**D**), CD8+ T cells (**E**), CD4/CD8 ratio (**F**) inferred from gene expression by TIMER. The correction coefficient (rho) was assessed by Spearman's rank correlation test.

Figure S16. The relationship between HLA loss and chromosomal copy number variations. (A) Comparison of allelic imbalance (AI) burden (number of AI events) in lesions with (purple) and without (green) HLA-LOH. (B) Comparison of copy number variation (CNV) burden (normalized as the percent of genes with CNV) in lesions with

(purple) and without (green) HLA-LOH. Willcoxon rank-sum test was used to assess thedifferences.

# 705 Figure S17. Promoter methylation and mutation burden from preneoplasia to

- invasive lung adenocarcinoma. The number of all nonsynonymous mutations in each
   histologic stage is shown as purple boxes and the number of nonsynonymous mutations
   from genes without promoter methylation (<30% CpG sites methylated) is shown as blue</li>
   boxes.
- 710 Figure S18. The potential impact of global methylation and immune infiltration. The
- correlation between global methylation levels (using LINE-1 as a surrogate marker) with

712 CD4+ T cells (A), CD4/CD8 ratio (B) inferred from immune gene expression by TIMER

- as well as Tregs (C) and Treg/CD8 ratio (D) measured by mIF. The correction coefficient
- (rho) was assessed by Spearman's rank correlation test.

# 715 SUPPLEMENTAL TABLES

- 716 **Table S1. Clinical characteristics and availability of different immune and molecular**
- 717 data
- 718 **Table S2. Statistics of Differentially Expressed Genes**
- 719
- 720

# 721 **REFERENCES**

- Aoyagi, Y., Yokose, T., Minami, Y., Ochiai, A., Iijima, T., Morishita, Y., Oda, T., Fukao, K., and Noguchi, M.
- 723 (2001). Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary
- adenocarcinoma. Cancer research *61*, 7950-7954.
- 725 Bakhoum, S. F., and Cantley, L. C. (2018). The Multifaceted Role of Chromosomal Instability in Cancer
- and Its Microenvironment. Cell 174, 1347-1360.
- 727 Barnett, R. (2017). Lung cancer. The Lancet *390*, 928.
- 728 Bastid, J., Cottalorda-Regairaz, A., Alberici, G., Bonnefoy, N., Eliaou, J., and Bensussan, A. (2013).
- ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene *32*, 1743-1751.
- 730 Bellomi, M., Veronesi, G., Trifirò, G., Brambilla, S., Bonello, L., Preda, L., Casiraghi, M., Borri, A., Paganelli,
- 731 G., and Spaggiari, L. (2010). Computed tomography-guided preoperative radiotracer localization of
- nonpalpable lung nodules. The Annals of thoracic surgery *90*, 1759-1764.
- Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate a Practical and Powerful
- Approach to Multiple Testing. J R Stat Soc B 57, 289-300.
- 735 Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip,
- 736 E., Holgado, E., et al. (2015). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell
- 737 Lung Cancer. N Engl J Med *373*, 1627-1639.
- 738 Cabrita, R., Lauss, M., Sanna, A., Donia, M., Larsen, M. S., Mitra, S., Johansson, I., Phung, B., Harbst, K.,
- and Vallon-Christersson, J. (2020). Tertiary lymphoid structures improve immunotherapy and survival in
- 740 melanoma. Nature *577*, 561-565.
- 741 Cesano, A. (2015). nCounter(®) PanCancer Immune Profiling Panel (NanoString Technologies, Inc.,
- 742 Seattle, WA). Journal for immunotherapy of cancer *3*, 42.
- 743 Chen, P. L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L.,
- 744 Gopalakrishnan, V., Wani, K., et al. (2016). Analysis of Immune Signatures in Longitudinal Tumor Samples
- 745 Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint
- 746Blockade. Cancer Discov 6, 827-837.
- Chen, R. Z., Pettersson, U., Beard, C., Jackson-Grusby, L., and Jaenisch, R. (1998). DNA hypomethylation
  leads to elevated mutation rates. Nature *395*, 89-93.
- 749 Chiosea, S., Jelezcova, E., Chandran, U., Luo, J., Mantha, G., Sobol, R. W., and Dacic, S. (2007).
- 750 Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer research *67*, 2345-2350.
- 751 Davoli, T., Uno, H., Wooten, E. C., and Elledge, S. J. (2017). Tumor aneuploidy correlates with markers of
- immune evasion and with reduced response to immunotherapy. Science 355.
- de Koning, H. J., van der Aalst, C. M., de Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A.,
- 754 Lammers, J.-W. J., Weenink, C., Yousaf-Khan, U., and Horeweg, N. (2020). Reduced lung-cancer mortality
- with volume CT screening in a randomized trial. New England Journal of Medicine *382*, 503-513.
- Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., and Schreiber, R. D. (2002). Cancer immunoediting: from
- immunosurveillance to tumor escape. Nature immunology *3*, 991-998.
- Dunn, G. P., Old, L. J., and Schreiber, R. D. (2004a). The immunobiology of cancer immunosurveillance
   and immunoediting. Immunity *21*, 137-148.
- Dunn, G. P., Old, L. J., and Schreiber, R. D. (2004b). The three Es of cancer immunoediting. Annu Rev Immunol *22*, 329-360.
- 762 Eden, A., Gaudet, F., Waghmare, A., and Jaenisch, R. (2003). Chromosomal instability and tumors
- 763 promoted by DNA hypomethylation. Science *300*, 455.
- 764 Francisco-Cruz, A., Parra, E. R., Tetzlaff, M. T., and Wistuba, II (2020). Multiplex Immunofluorescence
- Assays. Methods in molecular biology (Clifton, NJ) 2055, 467-495.
- Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., and Kroemer, G. (2017). The immune contexture in
- 767 cancer prognosis and treatment. Nature reviews Clinical oncology *14*, 717.

- Hu, X., Estecio, M. R., Chen, R., Reuben, A., Wang, L., Junya, F., Ying, L., Junya, F., Chow, C.-W.,
- 769 McGranahan, N., *et al.* (2020). Evolution of the DNA methylome from precancer to invasive lung 770 adenocarcinoma. medRxiv, 2020.2007.2011.20142745.
- Hu, X., Fujimoto, J., Ying, L., Fukuoka, J., Ashizawa, K., Sun, W., Reuben, A., Chow, C.-W., McGranahan,
- N., and Chen, R. (2019). Multi-region exome sequencing reveals genomic evolution from preneoplasia to
- 773 lung adenocarcinoma. Nature communications 10, 2978.
- Izumchenko, E., Chang, X., Brait, M., Fertig, E., Kagohara, L. T., Bedi, A., Marchionni, L., Agrawal, N., Ravi,
- 775 R., Jones, S., et al. (2015). Targeted sequencing reveals clonal genetic changes in the progression of early
- 1776 lung neoplasms and paired circulating DNA. Nature communications *6*, 8258.
- Jeschke, J., Bizet, M., Desmedt, C., Calonne, E., Dedeurwaerder, S., Garaud, S., Koch, A., Larsimont, D.,
- 778 Salgado, R., and Van den Eynden, G. (2017). DNA methylation–based immune response signature
- improves patient diagnosis in multiple cancers. The Journal of clinical investigation *127*, 3090-3102.
- Jung, H., Kim, H. S., Kim, J. Y., Sun, J. M., Ahn, J. S., Ahn, M. J., Park, K., Esteller, M., Lee, S. H., and Choi, J.
- K. (2019). DNA methylation loss promotes immune evasion of tumours with high mutation and copy
   number load. Nat Commun *10*, 4278.
- 783 Kankava, K., Kvaratskhelia, E., Burkadze, G., Kokhreidze, I., Gogokhia, N., and Abzianidze, E. (2018). Line-
- 1 Methylation in Blood and Tissues of Patients with Breast Cancer. Georgian Med News, 107-112.
- 785 Kaplinsky, J., and Arnaout, R. (2016). Robust estimates of overall immune-repertoire diversity from high-
- throughput measurements on samples. Nature communications 7, 11881-11881.
- 787 Kitamura, H., Kameda, Y., Ito, T., and Hayashi, H. (1999). Atypical adenomatous hyperplasia of the lung:
- implications for the pathogenesis of peripheral lung adenocarcinoma. American journal of clinicalpathology *111*, 610-622.
- Kramer, A., Green, J., Pollard, J., Jr., and Tugendreich, S. (2014). Causal analysis approaches in Ingenuity
  Pathway Analysis. Bioinformatics (Oxford, England) *30*, 523-530.
- 792 Kulkarni, M. M. (2011). Digital multiplexed gene expression analysis using the NanoString nCounter
- 793 system. Current protocols in molecular biology *Chapter 25*, Unit25B.10.
- Lavin, Y., Kobayashi, S., Leader, A., Amir, E.-a. D., Elefant, N., Bigenwald, C., Remark, R., Sweeney, R.,
- Becker, C. D., Levine, J. H., *et al.* Innate Immune Landscape in Early Lung Adenocarcinoma by Paired
  Single-Cell Analyses. Cell *169*, 750-765.e717.
- Li, T., Fu, J., Zeng, Z., Cohen, D., Li, J., Chen, Q., Li, B., and Liu, X. S. (2020). TIMER2.0 for analysis of
   tumor-infiltrating immune cells. Nucleic acids research.
- Liu, M., Zhou, J., Chen, Z., and Cheng, A. S. (2017). Understanding the epigenetic regulation of tumours
- and their microenvironments: opportunities and problems for epigenetic therapy. J Pathol 241, 10-24.
- 801 Maeshima, A. M., Tochigi, N., Yoshida, A., Asamura, H., Tsuta, K., and Tsuda, H. (2010). Clinicopathologic
- analysis of multiple (five or more) atypical adenomatous hyperplasias (AAHs) of the lung: evidence for
- 803 the AAH-adenocarcinoma sequence. Journal of thoracic oncology : official publication of the
- 804 International Association for the Study of Lung Cancer *5*, 466-471.
- Mansfield, A. S., Ren, H., Sutor, S., Sarangi, V., Nair, A., Davila, J., Elsbernd, L. R., Udell, J. B., Dronca, R. S.,
- Park, S., *et al.* (2018). Contraction of T cell richness in lung cancer brain metastases. Scientific reports *8*,
  2171.
- 808 Mascaux, C., Angelova, M., Vasaturo, A., Beane, J., Hijazi, K., Anthoine, G., Buttard, B., Rothe, F., Willard-
- 609 Gallo, K., Haller, A., et al. (2019). Immune evasion before tumour invasion in early lung squamous
- 810 carcinogenesis. Nature *571*, 570-575.
- 811 McGranahan, N., Furness, A. J., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M.,
- Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016). Clonal neoantigens elicit T cell immunoreactivity
- and sensitivity to immune checkpoint blockade. Science *351*, 1463-1469.

- McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J.,
- Veeriah, S., Van Loo, P., Herrero, J., et al. (2017). Allele-Specific HLA Loss and Immune Escape in Lung
  Cancer Evolution. Cell *171*, 1259-1271.e1211.
- 817 McWilliams, A., Tammemagi, M. C., Mayo, J. R., Roberts, H., Liu, G., Soghrati, K., Yasufuku, K., Martel, S.,
- 818 Laberge, F., and Gingras, M. (2013). Probability of cancer in pulmonary nodules detected on first
- 819 screening CT. New England Journal of Medicine *369*, 910-919.
- Min, J. H., Lee, H. Y., Lee, K. S., Han, J., Park, K., Ahn, M. J., and Lee, S. J. (2010). Stepwise evolution from
- a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: an
- observation for more than 10 years. Lung cancer (Amsterdam, Netherlands) 69, 123-126.
- 823 Mittal, D., Gubin, M. M., Schreiber, R. D., and Smyth, M. J. (2014). New insights into cancer
- immunoediting and its three component phases—elimination, equilibrium and escape. Current opinion
   in immunology 27, 16-25.
- 826 Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A.,
- and Smith, A. R. (2018). Organoid modeling of the tumor immune microenvironment. Cell *175*, 19721988. e1916.
- 829 Noguchi, M. (2010). Stepwise progression of pulmonary adenocarcinoma—clinical and molecular
- 830 implications. Cancer and Metastasis Reviews *29*, 15-21.
- 831 O'Donnell, J. S., Teng, M. W., and Smyth, M. J. (2019). Cancer immunoediting and resistance to T cell-
- based immunotherapy. Nature reviews Clinical oncology 16, 151-167.
- 833 Ohka, F., Natsume, A., Motomura, K., Kishida, Y., Kondo, Y., Abe, T., Nakasu, Y., Namba, H., Wakai, K.,
- 834 Fukui, T., et al. (2011). The global DNA methylation surrogate LINE-1 methylation is correlated with
- 835 MGMT promoter methylation and is a better prognostic factor for glioma. PLoS One *6*, e23332.
- Pan, L., Lu, M. P., Wang, J. H., Xu, M., and Yang, S. R. (2020). Immunological pathogenesis and treatment
  of systemic lupus erythematosus. World J Pediatr *16*, 19-30.
- Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M.
- 839 K., Pinto, J., Castrillon, J. A., et al. (2019). PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment
- via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.
- 841 Cancer Discov *9*, 722-737.
- Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature ReviewsCancer *12*, 252-264.
- Parra, E. R., Villalobos, P., Behrens, C., Jiang, M., Pataer, A., Swisher, S. G., William, W. N., Jr., Zhang, J.,
  Lee, J., Cascone, T., *et al.* (2018). Effect of neoadjuvant chemotherapy on the immune
- 846 microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence
  847 and image applysis approaches. Ummunother Cancer 6, 48
- and image analysis approaches. J Immunother Cancer 6, 48.
- Paulson, K., Voillet, V., McAfee, M., Hunter, D., Wagener, F., Perdicchio, M., Valente, W., Koelle, S.,
- Church, C., and Vandeven, N. (2018). Acquired cancer resistance to combination immunotherapy from
   transcriptional loss of class I HLA. Nature communications *9*, 1-10.
- Picarda, E., Ohaegbulam, K. C., and Zang, X. (2016). Molecular pathways: targeting B7-H3 (CD276) for
- human cancer immunotherapy. Clinical Cancer Research 22, 3425-3431.
- Porta-Pardo, E., and Godzik, A. (2016). Mutation Drivers of Immunological Responses to Cancer. Cancer
  Immunol Res 4, 789-798.
- 855 Pounds, S., and Morris, S. W. (2003). Estimating the occurrence of false positives and false negatives in
- 856 microarray studies by approximating and partitioning the empirical distribution of p-values.
- 857 Bioinformatics *19*, 1236-1242.
- Prakash, M. D., Munoz, M. A., Jain, R., Tong, P. L., Koskinen, A., Regner, M., Kleifeld, O., Ho, B., Olson,
- 859 M., and Turner, S. J. (2014). Granzyme B promotes cytotoxic lymphocyte transmigration via basement 860 membrane remodeling. Immunity *41*, 960-972
- 860 membrane remodeling. Immunity *41*, 960-972.


medRxiv preprint doi: https://doi.org/10.1101/2020.07.11.20142992; this version posted August 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


- Reuben, A., Gittelman, R., Gao, J., Zhang, J., Yusko, E. C., Wu, C. J., Emerson, R., Zhang, J., Tipton, C., Li, J.,
- 862 et al. (2017). TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An
- Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov 7,
- 864 1088-1097.
- Reuben, A., Zhang, J., Chiou, S. H., Gittelman, R. M., Li, J., Lee, W. C., Fujimoto, J., Behrens, C., Liu, X.,
- Wang, F., *et al.* (2020). Comprehensive T cell repertoire characterization of non-small cell lung cancer.
  Nat Commun *11*, 603.
- 868 Rosenthal, R., Cadieux, E. L., Salgado, R., Al Bakir, M., Moore, D. A., Hiley, C. T., Lund, T., Tanić, M.,
- Reading, J. L., and Joshi, K. (2019). Neoantigen-directed immune escape in lung cancer evolution. Nature
  567, 479-485.
- 871 Saito, K., Kawakami, K., Matsumoto, I., Oda, M., Watanabe, G., and Minamoto, T. (2010). Long
- interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell
  lung cancer. Clin Cancer Res *16*, 2418-2426.
- 874 Schreiber, R. D., Old, L. J., and Smyth, M. J. (2011). Cancer immunoediting: integrating immunity's roles 875 in cancer suppression and promotion. Science *331*, 1565-1570.
- 876 Schroeder, A., Mueller, O., Stocker, S., Salowsky, R., Leiber, M., Gassmann, M., Lightfoot, S., Menzel, W.,
- 877 Granzow, M., and Ragg, T. (2006). The RIN: an RNA integrity number for assigning integrity values to
- 878 RNA measurements. BMC molecular biology 7, 3.
- 879 Seki, M., and Akasaka, Y. (2007). Multiple lung adenocarcinomas and AAH treated by surgical resection.
- Lung cancer (Amsterdam, Netherlands) 55, 237-240.
- Serrano, A., Castro-Vega, I., and Redondo, M. (2011). Role of gene methylation in antitumor immune
   response: implication for tumor progression. Cancers (Basel) *3*, 1672-1690.
- Shah, W., Yan, X., Jing, L., Zhou, Y., Chen, H., and Wang, Y. (2011). A reversed CD4/CD8 ratio of tumor-
- infiltrating lymphocytes and a high percentage of CD4+ FOXP3+ regulatory T cells are significantly
- associated with clinical outcome in squamous cell carcinoma of the cervix. Cellular & molecular
- immunology *8*, 59-66.
- Shukla, S. A., Rooney, M. S., Rajasagi, M., Tiao, G., Dixon, P. M., Lawrence, M. S., Stevens, J., Lane, W. J.,
- 888 Dellagatta, J. L., Steelman, S., et al. (2015). Comprehensive analysis of cancer-associated somatic
- 889 mutations in class I HLA genes. Nature biotechnology 33, 1152-1158.
- Siegel, R. L., Miller, K. D., and Jemal, A. (2020). Cancer statistics, 2020. CA Cancer J Clin 70, 7-30.
- Sivakumar, S., Lucas, F. A. S., McDowell, T. L., Lang, W., Xu, L., Fujimoto, J., Zhang, J., Futreal, P. A.,
- 892 Fukuoka, J., Yatabe, Y., *et al.* (2017). Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals
- 893Divergent Modes to Lung Adenocarcinoma. Cancer research 77, 6119-6130.
- Soto-Pantoja, D. R., Terabe, M., Ghosh, A., Ridnour, L. A., DeGraff, W. G., Wink, D. A., Berzofsky, J. A.,
- and Roberts, D. D. (2014). CD47 in the tumor microenvironment limits cooperation between antitumor
   T-cell immunity and radiotherapy. Cancer research *74*, 6771-6783.
- Tan, W. L., Jain, A., Takano, A., Newell, E. W., Iyer, N. G., Lim, W. T., Tan, E. H., Zhai, W., Hillmer, A. M.,
- Tam, W. L., and Tan, D. S. W. (2016). Novel therapeutic targets on the horizon for lung cancer. The Lancet Oncology *17*, e347-e362.
- 900 Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Yang, T.-H. O., Porta-Pardo, E., Gao, G. F.,
- 901 Plaisier, C. L., and Eddy, J. A. (2018). The immune landscape of cancer. Immunity *48*, 812-830. e814.
- 902 Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell,
- 903 C. A., Riely, G. J., Van Schil, P. E., et al. (2011). International association for the study of lung
- 904 cancer/american thoracic society/european respiratory society international multidisciplinary
- 905 classification of lung adenocarcinoma. Journal of thoracic oncology : official publication of the
- 906 International Association for the Study of Lung Cancer *6*, 244-285.
- 907 Tschopp, J., Masson, D., and Stanley, K. K. (1986). Structural/functional similarity between proteins
- 908 involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis. Nature *322*, 831-834.


medRxiv preprint doi: https://doi.org/10.1101/2020.07.11.20142992; this version posted August 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

- 909 Van Loo, P., Nordgard, S. H., Lingjaerde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V. J.,
- 910 Marynen, P., Zetterberg, A., Naume, B., et al. (2010). Allele-specific copy number analysis of tumors. 911 Proc Natl Acad Sci U S A 107, 16910-16915.
- 912 Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., Jr., and Kinzler, K. W. (2013).
- 913 Cancer genome landscapes. Science 339, 1546-1558.
- 914 Wang, J., Jiang, D., Zheng, X., Li, W., Zhao, T., Wang, D., Yu, H., Sun, D., Li, Z., Zhang, J., et al. (2020).
- 915 Tertiary Lymphoid Structure and CD8 T Cell Exclusion in Minimally Invasive Adenocarcinoma. medRxiv, 916 2020.2008.2003.20166991.
- 917 Wang, X., Zhang, B., Yang, Y., Zhu, J., Cheng, S., Mao, Y., Feng, L., and Xiao, T. (2019). Characterization of
- 918 Distinct T Cell Receptor Repertoires in Tumor and Distant Non-tumor Tissues from Lung Cancer Patients.
- 919 Genomics Proteomics Bioinformatics 17, 287-296.
- 920 Weichert, W., and Warth, A. (2014). Early lung cancer with lepidic pattern: adenocarcinoma in situ,
- 921 minimally invasive adenocarcinoma, and lepidic predominant adenocarcinoma. Current opinion in
- 922 pulmonary medicine 20, 309-316.
- 923 Wherry, E. J., and Kurachi, M. (2015). Molecular and cellular insights into T cell exhaustion. Nat Rev
- 924 Immunol 15, 486-499.
- 925 Yarchoan, M., Johnson III, B. A., Lutz, E. R., Laheru, D. A., and Jaffee, E. M. (2017). Targeting neoantigens
- 926 to augment antitumour immunity. Nature Reviews Cancer 17, 209.


927










#### В AAH








-1 -0.9-0.8-0.7-0.6-0.5-0.4-0.3-0.2-0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1



В

## Distribution of T-cell clones




Α


Log2 ratio


#### CD47: p-value = 5.947e-04


CD276: p-value = 8.774e-10


#### CTLA4: p-value = 1.400e-04












Ε

Β

GZMB: p-value = 5.438e-10





Histology



С

PRF1: p-value = 1.913e-08










Figure S4












Figure S7














Figure S12






Α

EGFR-Mut 
KRAS-Mut 
WT 획 EGFR-Mut 획 KRAS-Mut 🕸 WT EGFR-Mut 
KRAS-Mut 
WT 5.050e-01 2.577e-01 8.071e-01 0.70 6.792e-02 6.171e-01 7.389e-01 7.165e-01 9.535e+01 8.150e-01 1.661e-01 8.878e-01 2.320e-01 0.26 0.65 0.60 0.55 0.50 0.50 0.45 Cytotoxic T cells 3 2 0.20 1 0.40 AAH ADC ADC AİS MİA ADC AİS MİA AÁH AIS MİA AÁH Stages Stages Stages D Ε F

Β

С








Figure S15

